IRX4

Across TCGA pan-cancer cohorts, IRX4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IRX4 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher IRX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IRX4 expression acts as an unfavorable survival marker.

ACC, LUSC, and PRAD are the cancer types where IRX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
LUSC	OS	Median	All	0.178	0.762	.003	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	OS	Median	All	0.333	0.780	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IRX4–ACC (OS)

Open the ACC breakdown →